A Phase 1 Trial of ZN-A-1041 Enteric Capsules or Combination in Patients With HER2-Positive Advanced Solid Tumors

Phase 1

Recruiting

• Conditions: Advanced Solid Tumors; HER2-positive Breast Cancer
• Interventions: Drug: ZN-A-1041 50mg BID; Drug: ZN-A-1041 100mg BID; Drug: ZN-A-1041 200mg BID; Drug: ZN-A-1041 400mg BID; Drug: ZN-A-1041 600mg BID; Drug: ZN-A-1041 800mg BID; Drug: ZN-A-1041 1000mg BID; Drug: ZN-A-1041 + T-DM1 3.6 mg/kg iv. for Phase1b; Drug: ZN-A-1041 + T-Dxd 5.4 mg/kg iv. for Phase1b; Drug: ZN-A-1041 + PHESGO / Herceptin plus Perjeta injection for Phase1b; Drug: ZN-A-1041 + T-DM1 3.6 mg/kg iv. for Phase1c; Drug: ZN-A-1041 + T-Dxd 5.4 mg/kg iv. for Phase1c; Drug: ZN-A-1041 + PHESGO / Herceptin plus Perjeta injection for Phase1c

• Registration Number: NCT05593094
• Lead Sponsor: Suzhou Zanrong Pharma Limited

Brief Summary

This will be a Phase 1, multicenter, open-label trial to evaluate the safety, tolerability, PK and efficacy of ZN-A-1041 as a monotherapy or in combination in patients with HER2-positive advanced solid tumors with or without brain metastases.

The study will consist of three phases: Phase 1a (dose escalation with ZN-A-1041 monotherapy), Phase 1b (dose escalation with ZN-A-1041 combination therapy) and Phase 1c (dose expansion with ZN-A-1041 combination therapy).

Detailed Description

Phase 1a of the study will adopt the "modified 3+3" dose escalation design with a total of 7 planned dose levels. Patients with HER2-positive advanced solid tumor (including those with brain metastases) will be enrolled to receive a single-dose administration of ZN-A-1041 followed by multiple-dose administration of ZN-A-1041.Phase 1b of the study will adopt the "traditional 3+3" dose escalation design. The dose levels will be based on the results of the Phase 1a study and the results of a food effect study. In Phase 1b, patients with unresectable locally-advanced or metastatic HER2+ breast cancer with and without brain metastasis will be enrolled in three arms: Arm1 will receive multiple doses of ZN-A-1041 in combination with T-DM1; Arm2 will receive multiple doses of ZN-A-1041 in combination with T-DXd. Arm 3 will receive multiple doses of ZN-A-1041 in combination with PHESGO or Herceptin plus Perjeta after Herceptin plus Perjeta and 4-8-cycle treatment of taxane. Patients will be assessed for an appropriate arm by the sponsor and the investigator at the time of consent. Patients with unresectable locally-advanced or metastatic HER2+ breast cancer with and without brain metastasis are planned to be enrolled in Phase 1c of the study: Arm1 will receive multiple doses of ZN-A-1041 in combination with T-DM1; Arm2 will receive multiple doses of ZN-A-1041 in combination with T-DXd; Arm 3 will receive multiple doses of ZN-A-1041 in combination with PHESGO or Herceptin plus Perjeta after Herceptin plus Perjeta or T-DXd based induction regimen. Patients will be assessed for an appropriate arm by the sponsor and the investigator at the time of consent. Arm1 of Phase 1c can start independently after the DLT observation period of the last patient in Phase 1b Arm1. Arm 2 of Phase 1c can start independently after the DLT observation of the last patient in Phase 1b Arm 2. Arm 3 of Phase 1c can start independently after the DLT observation of the last patient in Phase 1b Arm 3. The dose levels used in Phase 1c will be based on the recommended doses obtained from the Phase 1b study.

Each phase of the study includes a screening period (from 28 days prior to the first administration of the study drug), a treatment period (until there are no clinical benefits as deemed by the Investigator, disease progression, death, intolerable toxicity, withdrawal of informed consent, loss of follow-up, or the start of new anti-tumor treatment), and a follow-up period (until 28 days after the last administration of the study drug). During the trial, the safety, tolerability, PK and efficacy data of ZN-A-1041 as monotherapy and in combination in the subjects will be collected and analyzed, thereby providing RP2D for subsequent future clinical trials.

Study Timeline

• Study Start: 2020-10-15
• Study First Submitted: 2022-10-17
• Study First Submitted QC: 2022-10-22
• Study First Posted: 2022-10-25
• Status Verified: 2024-08
• Last Update Submitted: 2024-08-29
• Last Update Posted: 2024-09-03
• Primary Completion: 2025-10-30
• Study Completion: 2026-10-30

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 210

Inclusion Criteria

1. ECOG performance status of 0 to 1

2. HER2 positive is defined as Immunohistochemistry (IHC) (++) and Fluorescence In Situ Hybridization (FISH) positive, or IHC (+++).

3. Phase 1a study will enroll patients with unresectable or metastatic HER2-positive advanced solid tumor.

   For patients who have no brain metastases, the following criteria should be met:

   1. Patients should be relapsed or refractory to existing therapy(ies) or have been intolerant of such therapies
   2. Patients with HER2-positive breast cancer should have previously received Trastuzumab, Pertuzumab, Trastuzumab emtansine(T-DM1) and a taxane.
   3. Patients with HER2-positive gastric cancer must have previously received trastuzumab.
   4. Have measurable or non-measurable disease assessable by RECIST 1.1.

   For patients with brain metastasis, the following criteria should be met:

   1. Patients with HER2-positive breast cancer must have received prior treatment with Trastuzumab, Pertuzumab and T-DM1, and a taxane or patient declined the above treatment.
   2. Patients with HER2-positive gastric cancer must have previously received Trastuzumab
   3. Do not require immediate local treatment during the trial period, and meet either of the following two criteria: i) For patients who have received previous local treatment (surgery, whole brain radiotherapy (WBRT) and stereotactic radiosurgery (SRS)) for brain metastases, stable or progression of intracranial lesions is required. Interval from prior local therapy could be 3 weeks from WBRT and 2 weeks from SRS; ii) Symptomatic or not, patient has not received previous local treatment (surgery or radiotherapy) for brain metastases as long as no local therapy is needed during the trial period.

   For patients who have received previous tyrosine kinase inhibitor (TKI) treatment, chemotherapy, antibody, or antibody-drug conjugate (ADC), the interval between the last treatment and the first administration of the study drug in this trial should be at least 2 weeks.

4. Phase 1b and Phase 1c study will enroll patients with unresectable locally advanced or metastatic HER2+ breast cancer.

   For Phase 1b patients who have no brain metastases, the following criteria should be met:

   1. For arm 1 and arm 2, patients should be relapsed or refractory to existing therapy(ies), with a history of prior treatment with trastuzumab and a taxane. For arm3, patients have received 4-8 cycles (21-day cycles) of previous treatment with trastuzumab, pertuzumab, and taxane as first-line therapy for advanced HER2+ breast cancer with no evidence of disease progression.
   2. Have measurable or non-measurable disease assessable by RECIST 1.1

   For Phase 1c patients who have no brain metastases, the following criteria should be met:

   1. For arm 1 and arm 2, patients should be refractory to existing therapy(ies), with a history of prior treatment with trastuzumab. For arm3, patients have received a pertuzumab plus trastuzumab or T-DXd for advanced HER2+breast cancer with no evidence of disease progression.
   2. In arms 1 and 2, patients should have at least one measurable lesion either extracranially or intracranially per RECIST v1.1.

   For patients with brain metastasis, the following criteria should be met:

   1. For arm 1 and arm 2 of phase 1b, patients should be relapsed or refractory to existing therapy(ies), with a history of prior treatment with trastuzumab and a taxane. For arm3, patients have received 4-8 cycles (21-day cycles) of previous treatment with trastuzumab, pertuzumab, and taxane as first-line therapy for advanced HER2+ breast cancer with no evidence of disease progression. For arm 1 and arm 2 of phase 1c, patients should be refractory to existing therapy(ies), with a history of prior treatment with trastuzumab. For arm3, patients have received previous treatment with a pertuzumab plus trastuzumab or T-DXd for advanced HER2+ breast cancer with no evidence of disease progression (except brain metastases).
   2. Do not require immediate local treatment during the trial period, and meet either of the following two criteria: i) For patients who have received previous local treatment (surgery, whole brain radiotherapy (WBRT) and stereotactic radiosurgery (SRS)) for brain metastases, stable or progression of intracranial lesions is required. Interval from prior local therapy could be 3 weeks from WBRT, 2 weeks from SRS and 4 weeks from surgery; ii) Symptomatic or not, patient has not received previous local treatment (surgery or radiotherapy) for brain metastases as long as no local therapy is needed during the trial period.

5. Suspected or confirmed leptomeningeal metastasis are allowed.

6. In Phase 1b arm1 and arm2, patients who have received previous tyrosine kinase inhibitor (TKI) treatment, chemotherapy, antibody, or antibody-drug conjugate (ADC), the interval between the last treatment and the first administration of the study drug in this trial should be at least 2 weeks. For arm3, patients should not have prior treatment for unresectable locally-advanced or metastatic HER2+ breast cancer with and without brain metastasis, except for ongoing Herceptin, Perjeta or PHESGO and taxane.

7. In Phase 1c arm1 and arm2, Patients should not have received prior treatment with tucatinib, afatinib, or any other investigational anti-HER2, anti-EGFR, or HER2 TKI agent. Prior treatment with lapatinib or neratinib within 12 months of starting study treatment (except in cases where they were given for ≤ 21 days and was discontinued for reasons other than disease progression or severe toxicity). Prior treatment with pyrotinib for recurrent of mBC (except in cases where pyrotinib was given for ≤ 21 days and was discontinued for reasons other than disease progression or severe toxicity). For arm3, patients should not have prior treatment for unresectable locally-advanced or metastatic HER2+ breast cancer with and without brain metastasis, except for ongoing Herceptin, Perjeta or PHESGO or T-Dxd based induction.

Exclusion Criteria

1. Subjects who have participated in any clinical study or received any clinical study drug within 4 weeks prior to the first administration except for on-going Herceptin, Perjeta or PHESGO in arm3

2. CNS Exclusion - Based on screening brain MRI and clinical assessment

   1. Progressive neurologic impairment or increased intracranial pressure (including nausea, vomiting, blurred vision, headache, epilepsy, etc.)
   2. Any intracranial lesion thought to require immediate local therapy
   3. Require antiepileptic treatment (except for these patients with stable seizures require continuous Levetiracetam therapy).
   4. Ongoing use of systemic corticosteroids for control of symptoms of brain metastases at a total daily dose of > 2 mg of dexamethasone (or equivalent)

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SEQUENTIAL

Arm && Interventions

Group	Intervention	Description
ZN-A-1041 50mg	ZN-A-1041 50mg BID	Phase 1a: Subjects will be given ZN-A-1041 orally 50mg Bid, for 21days as one cycle
ZN-A-1041 100mg	ZN-A-1041 100mg BID	Phase 1a: Subjects will be given ZN-A-1041 orally 100mg Bid, for 21days as one cycle
ZN-A-1041 200mg	ZN-A-1041 200mg BID	Phase 1a: Subjects will be given ZN-A-1041 orally 200mg Bid, for 21days as one cycle
ZN-A-1041 400mg	ZN-A-1041 400mg BID	Phase 1a: Subjects will be given ZN-A-1041 orally 400mg Bid, for 21days as one cycle
ZN-A-1041 600mg	ZN-A-1041 600mg BID	Phase 1a: Subjects will be given ZN-A-1041 orally 600mg Bid, for 21days as one cycle
ZN-A-1041 800mg	ZN-A-1041 800mg BID	Phase 1a: Subjects will be given ZN-A-1041 orally 800mg Bid, for 21days as one cycle
ZN-A-1041 1000mg	ZN-A-1041 1000mg BID	Phase 1a: Subjects will be given ZN-A-1041 orally 1000mg Bid, for 21days as one cycle
1b: ZN-A-1041 + T-DM1 3.6 mg/kg iv.	ZN-A-1041 + T-DM1 3.6 mg/kg iv. for Phase1b	Phase 1b Arm1: 1. If the MTD of ZN-A-1041 is identified in Phase 1a study: The 2 tentative dose levels of ZN-A-1041 are MTD-1 (Level 1) and MTD (Level 2) 2. If the MTD is still not reached at the maximum dose level in Phase 1a study, the maximum dose level of ZN-A-1041 in Phase 1a will be used in Phase 1b study.
1b: ZN-A-1041 + T-Dxd 5.4 mg/kg iv.	ZN-A-1041 + T-Dxd 5.4 mg/kg iv. for Phase1b	Phase 1b Arm2: 1. If the MTD of ZN-A-1041 is identified in Phase 1a study: The 2 tentative dose levels of ZN-A-1041 are MTD-1 (Level 1) and MTD (Level 2) 2. If the MTD is still not reached at the maximum dose level in Phase 1a study, the maximum dose level of ZN-A-1041 in Phase 1a will be used in Phase 1b study.
1b: ZN-A-1041 + PHESGO / Herceptin plus Perjeta	ZN-A-1041 + PHESGO / Herceptin plus Perjeta injection for Phase1b	Phase 1b Arm3: 1. If the MTD of ZN-A-1041 is identified in Phase 1a study: The 2 tentative dose levels of ZN-A-1041 are MTD-1 (Level 1) and MTD (Level 2) 2. If the MTD is still not reached at the maximum dose level in Phase 1a study, the maximum dose level of ZN-A-1041 in Phase 1a will be used in Phase 1b study.
1c: ZN-A-1041 + T-DM1 3.6 mg/kg iv.	ZN-A-1041 + T-DM1 3.6 mg/kg iv. for Phase1c	Phase 1c Arm1: The dose levels of ZN-A-1041 in the Phase 1c study will be the recommended doses determined in the Phase 1b study.
1c: ZN-A-1041 + T-Dxd 5.4 mg/kg iv.	ZN-A-1041 + T-Dxd 5.4 mg/kg iv. for Phase1c	Phase 1c Arm2: The dose levels of ZN-A-1041 in the Phase 1c study will be the recommended doses determined in the Phase 1b study.
1c: ZN-A-1041 + Herceptin plus Perjeta/PHESGO	ZN-A-1041 + PHESGO / Herceptin plus Perjeta injection for Phase1c	Phase 1c Arm3: The dose levels of ZN-A-1041 in the Phase 1c study will be the recommended doses determined in the Phase 1b study.

Primary Outcome Measures

Name	Time	Method
The Incidence of Treatment-Emergent Adverse Events of ZN-A-1041 as a monotherapy in Phase 1a	23 days	Dose at which no more than one out of six patient at the same dose level experiences a probable drug-related dose limiting toxicity.
The Incidence of Treatment-Emergent Adverse Events of ZN-A-1041 in combination with T-DM1 or with T-DXd, or in combination with PHESGO or Herceptin plus Perjeta	21 days	Dose at which no more than one out of six patient at the same dose level experiences a probable drug-related dose limiting toxicity.
RP2D Dose	through study completion, an average of 1 year	To evaluate the safety of ZN-A-1041 in combination with T-DM1 or with T-DXd, or in combination with PHESGO or Herceptin plus Perjeta in patients on the RP2D Dose

Secondary Outcome Measures

Name	Time	Method
Anti-drug antibodies (ADAs) evaluation in Phase 1c	through study completion, an average of 2 year	To assess the incidence of ADAs
overall Response Rate (ORR)	through study completion, an average of 2 year	The preliminary efficacy of ZN-A-1041 as a monotherapy or combination in Phase 1a,phase 1b and 1c
Plasma, urine and potentially CSF level of ZN-A-1041 and its main metabolites	From baseline to Cycle 9 (each cycel is 21 days)	To assess the PK of ZN-A-1041 and its major metabolites
Serum level of combination drugs in phase 1c	through study completion, an average of 2 year	To assess the serum concentration of combination drugs
Progression free survival(PFS)	through study completion, an average of 2 year	The preliminary efficacy of ZN-A-1041 as a monotherapy or combination in Phase 1a,phase 1b and 1c

Trial Locations

Locations (23)

ACRC/Arizona Clinical Research Center, Inc; 🇺🇸 Tucson, Arizona, United States

TOI Clinical Research; 🇺🇸 Cerritos, California, United States

Innovative Clinical Research Institute; 🇺🇸 Whittier, California, United States

Duke Cancer Institute; 🇺🇸 Durham, North Carolina, United States

Andrew Love Cancer Center; 🇦🇺 Geelong, Victoria, Australia

Sunshine Hospital - Australia; 🇦🇺 St Albans, Victoria, Australia

Centre Léon Bérard Centre Régional de Lutte Contre Le Cancer Rhône Alpes; 🇫🇷 Lyon, France

Institut Claudius Regaud - PPDS; 🇫🇷 Toulouse, France

Centre Oscar Lambret - PPDS; 🇫🇷 Lille, Nord, France

Auckland City Hospital; 🇳🇿 Auckland, New Zealand

Instituto Oncologico Dr. Rosell-Hospital Universitari Dexeus-Grupo Quironsalud; 🇪🇸 Barcelona, Spain

Hospital Clinic de Barcelona; 🇪🇸 Barcelona, Spain

Instituto de Investigacion Oncologica Vall dHebron (VHIO) - EPON; 🇪🇸 Barcelona, Spain

Hospital Universitario de Jaen; 🇪🇸 Jaén, Spain

Fundacion Instituto Valenciano de Oncologia; 🇪🇸 Valencia, Spain

Hospital Clinico Universitario de Santiago; 🇪🇸 Santiago de Compostela, Spain

Hospital Universitario Virgen Macarena; 🇪🇸 Sevilla, Spain

Hospital Universitario Ramon y Cajal; 🇪🇸 Madrid, Spain

The Christie - PPDS; 🇬🇧 Manchester, Lancashire, United Kingdom

Md Anderson Cancer center; 🇺🇸 Houston, Texas, United States

Hospital Clinico San Carlos; 🇪🇸 Madrid, Spain

Dana-Farber Cancer Insitute; 🇺🇸 Boston, Massachusetts, United States

Barbara Ann Karmanos Cancer center; 🇺🇸 Detroit, Michigan, United States